User:MomentousOccassion/sandbox

Women's Alzheimer's Movement

Maria Shriver

Brooke Eby - ALS

https://www2.lehigh.edu/news/brooke-eby-10-an-advocate-in-the-fight-against-als

https://www.today.com/health/essay/als-diagnosis-at-33-rcna69352

Bryan Randall

https://brevardalz.org/alzheimers-info/famous-people-with-dementia/

Banner Alzheimer's Institute

Dr E. Reiman and Dr P Tariot

https://www.nia.nih.gov/health/alzheimers-disease-research-centers

https://clinicaltrials.gov/study/NCT01998841

Crenezumab

Banner Alzheimer’s Institute is a research and care center for Alzheimer’s disease and related dementias that also offers support services for families of individuals with these conditions. Its mission is to end Alzheimer’s disease without losing a generation, set a new standard of care for patients and families, and forge a model of collaboration in biomedical research.

The Institute was founded in 2006 in Phoenix, Arizona as part of Banner Health. It now has facilities in Phoenix and Tucson, as well as a sister organization in Sun City, Arizona – Banner Sun Health Research Institute. Its co-founders are Dr. Eric Reiman, who is currently the Institute’s executive director, and Dr. Pierre N. Tariot.

The Institute collaborates with a wide range of international, national and local scientific, medical, academic and community partners, including the Arizona Alzheimer’s Consortium, the AD Genetics Consortium, ASU-Banner Neurodegenerative Research Collaborative, Dementia ECHO, and the Brain and Body Donation Program.

Research and Scientific Contributions
Banner Alzheimer’s Institute receives millions of dollars in funding to research ways to fight Alzheimer’s and related dementias and increase understanding of these conditions. Studies include prevention trials that work with cognitively normal individuals that may be at an increased risk of developing Alzheimer’s related symptoms as well as studies for individuals with memory loss including Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Funding comes from agencies such as the National Institutes of Health (NIH) – particularly the National Institute on Aging - as well as other organizations, including the Banner Alzheimer’s Foundation.

Prevention Research
In May of 2012, Banner Alzheimer’s Institute announced the Alzheimer’s Prevention Initiative (API), a large partnership between researchers, academics, and other stakeholders, to find and support approval for an effective Alzheimer’s prevention therapy by 2025. Its work includes conducting clinical trials in adults at high risk for developing symptoms of Alzheimer’s, operating large-scale participant recruitment registries, developing data and biological sharing programs, and developing and using new research methods and strategies to evaluate prevention treatments. Its most significant research projects have been the Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial and the Generation Program.

API ADAD Colombia Trial
The API ADAD Colombia Trial was the Institute’s first prevention trial. In 2012 along with the NIH, the University of Antioquia in Colombia, and Genentech (a member of the Roche Group), announced the $100 million, multi-year trial. It was the first Alzheimer’s prevention study in cognitively healthy people with near-certainty of developing Alzheimer’s disease because of a rare genetic mutation. The API ADAD trial investigated whether an experimental amyloid-fighting treatment (crenezumab) could stave off the disease in members of a large extended family in Colombia who share a rare genetic mutation that typically triggers Alzheimer’s symptoms around age 45. It was designed to determine whether the drug could reduce their chances of developing symptoms, preserve their memory and thinking abilities and slow the progression of Alzheimer’s biomarkers. The trial compared cognitive and biological changes over 5-8 years in 252 cognitively unimpaired members of this kindred – family members who have the rare Colombian “Paisa” mutation and members who do not. In June 2022, researchers announced the study’s final results – that crenezumab failed to show a statistically significant clinical benefit in slowing or preventing cognitive decline in those with the genetic mutation that causes early onset Alzheimer’s disease.

API Generation Program
BAI’s second major prevention research initiative was the API Generation Program – two clinical trials that focused on potential preventive treatments for cognitively healthy people at higher genetic risk of developing Alzheimer’s disease.

Alzheimer’s Prevention Registry
Other Areas of Research

BAI's study portfolio also includes trials with investigational therapeutic interventions, several non-interventional longitudinal studies, and brain imaging-only trials that are aimed at advancing knowledge of Alzheimer’s disease and other dementias. These studies include: Medicines that may help memory and thinking, Drugs that hope to stop or slow signs of the disease, Immunotherapies such as vaccines aimed at helping your body fight off the disease, Studying people with very early signs of memory loss, New techniques for taking pictures of the brain, New ways to spot the disease early on and Studies to understand the disease in minority populations such as Hispanic, Native American or African American.

Programs
Banner Alzheimer’s Institute offers programs and resources to support prevention, clinical care, research and education, and community outreach.

Clinical Neuropsychologists
The Institute’s clinical neuropsychologists evaluate brain function to determine possible causes of changes to a patient’s memory. They recommend strategies for maintaining brain health and offer cognitive training to patients

Banner Neuro Wellness
This program complements medical care through wellness classes, support groups, lectures, social activities and Parkinson’s-specific exercises to improve quality of life.

Dementia Care Partners Program

Dementia Untangled

First Responder Training

Facilities
Phoenix, Tucson

Sun City

Memory Care Centers
Key Staff


 * Dr. Eric Reiman: Co-founder and executive director of Banner Alzheimer’s Institute
 * Dr. Pierre Tariot: Co-founder of Banner Alzheimer’s Institute
 * Dr. Robert Alexander: Chief scientific officer of the Alzheimer’s Prevention Initiative

Sourcing
https://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html

https://www.usatoday.com/story/news/health/2022/06/16/closely-watched-alzheimers-study-fails-prevent-advance-disease/7639930001/

https://www.usatoday.com/story/news/health/2022/06/16/closely-watched-alzheimers-study-fails-prevent-advance-disease/7639930001/

https://www.usatoday.com/story/news/health/2022/08/19/aerobic-exercise-and-simple-stretching-may-both-lower-alzheimers-risk/10328732002/

https://www.nytimes.com/2022/06/16/health/alzheimers-drug-crenezumab.html#:~:text=The%20drug%2C%20crenezumab%2C%20failed%20to,effective%20therapies%20for%20the%20disease

https://www.guidestar.org/profile/20-4862361

https://hbr.org/sponsored/2019/09/arizona-the-new-frontier-in-technology-and-health-care